Linking Case Processing Outputs to Signal Detection and Aggregate Reports Linking Case Processing Outputs to Signal Detection and Aggregate Reports In the landscape of pharmacovigilance, effective monitoring and reporting of adverse drug reactions (ADRs) are integral to drug safety and risk management. This regulatory explainer manual outlines the framework for linking case processing outputs to signal detection and aggregate reports across regulatory environments, particularly focusing on GVP guidelines compliant with US (FDA), EU (EMA), and UK (MHRA) regulations. Context Pharmacovigilance (PV) is a critical component of the pharmaceutical lifecycle, designed to identify, assess, and mitigate risks associated with drug use….

Common Audit and Inspection Findings in Case Processing and ICSR Flows Common Audit and Inspection Findings in Case Processing and ICSR Flows In the global landscape of pharmaceuticals, the importance of pharmacovigilance cannot be overstated. Ensuring drug safety and risk management is vital for compliance with regulatory expectations. The process of case processing and the submission of Individual Case Safety Reports (ICSRs) is an essential component of pharmacovigilance that operates under stringent guidelines and regulations. Context The field of Regulatory Affairs (RA) is tasked with ensuring that all pharmaceutical products adhere to the relevant regulatory frameworks set forth by bodies…

Handling Literature Cases and Special Source Types Without Losing Control Handling Literature Cases and Special Source Types Without Losing Control In the field of pharmacovigilance, managing literature cases and special source types is vital to ensuring drug safety and regulatory compliance. With the increasing amount of data sources available, pharmaceutical entities must adeptly navigate the complexities of adverse event reporting while adhering to Good Pharmacovigilance Practice (GVP) guidelines. This article serves as a comprehensive regulatory explainer manual, detailing regulatory expectations and providing guidance for Regulatory Affairs (RA) teams, CMC, and labelling professionals. Context Pharmacovigilance is defined as the science and…

Designing QA Sampling and QC Strategies for Case Handling Designing QA Sampling and QC Strategies for Case Handling Regulatory Affairs Context Pharmacovigilance (PV) encompasses the science and activities related to the detection, assessment, understanding, and prevention of adverse effects or any other drug-related problem. As the industry continues to evolve, the need for robust pharmacovigilance systems becomes paramount for ensuring drug safety and compliance with the regulatory frameworks established by authorities such as the FDA, EMA, and MHRA. This article provides a deep dive into the regulatory requirements and practicalities surrounding quality assurance (QA) sampling and quality control (QC) strategies…

System Interfaces Between Safety Databases, EudraVigilance and FAERS System Interfaces Between Safety Databases, EudraVigilance and FAERS In the domain of pharmacovigilance, regulatory compliance is critical to ensure the safety of medicinal products. This regulatory explainer manual delves into the system interfaces between key safety databases, particularly EudraVigilance and FAERS, outlining the regulatory framework, documentation requirements, and agency expectations. The primary audience for this article includes Regulatory Affairs professionals, CMC teams, and Labelling specialists in the US and EU pharmaceutical landscape. Regulatory Context Pharmacovigilance (PV) is defined by the World Health Organization (WHO) as the science and activities relating to the…

Managing Late Cases, Follow-Up and Data Clarifications with Sites Managing Late Cases, Follow-Up and Data Clarifications with Sites Context The landscape of pharmacovigilance and drug safety is increasingly complex, driven by stringent regulatory frameworks established by agencies such as the FDA in the United States, EMA in Europe, and MHRA in the United Kingdom. In this ever-evolving environment, the submission of Individual Case Safety Reports (ICSRs) is crucial for ensuring that potential risks associated with pharmaceuticals are adequately monitored and mitigated. As the volume of cases continues to rise, the need for robust regulatory compliance consulting services has never been…

Automation, AI and Robotics in Case Intake and Triage: Hype vs Reality Automation, AI and Robotics in Case Intake and Triage: Hype vs Reality Regulatory Affairs Context In the realm of pharmacovigilance, the need for compliance with Good Pharmacovigilance Practices (GVP) is paramount. Regulatory Agencies such as the FDA in the US, EMA in the EU, and MHRA in the UK demand that pharmacovigilance systems are robust, ensuring the safety and efficacy of pharmaceutical products. The integration of automation, Artificial Intelligence (AI), and robotics into these processes promises enhanced efficiency and accuracy in case intake and triage activities, thereby raising…

Business Continuity Planning for Case Processing Disruptions Business Continuity Planning for Case Processing Disruptions In the dynamic landscape of pharmacovigilance, ensuring business continuity in case processing is critical for maintaining drug safety and regulatory compliance. With increasing scrutiny from regulatory agencies like the FDA, EMA, and MHRA, it is essential for pharmaceutical and biotech organizations to implement effective business continuity plans (BCPs) that address disruptions in Individual Case Safety Report (ICSR) submissions and reporting environments. This article serves as a regulatory explainer manual, delineating the applicable regulations, guidelines, agency expectations, best practices, and common deficiencies to guide Regulatory Affairs (RA)…

Case Studies: How Poor Case Handling Derailed PV Inspections Case Studies: How Poor Case Handling Derailed PV Inspections Regulatory Affairs Context In the field of pharmacovigilance (PV), the importance of efficient case processing and compliance cannot be understated. As regulatory authorities like the FDA, EMA, and MHRA enforce strict guidelines for drug safety and risk management, the need for robust case handling processes becomes crucial. This comprehensive article elucidates the challenges faced when managing Individual Case Safety Reports (ICSRs) and underscores how poor case handling can lead to significant regulatory setbacks, including failed inspections. Legal/Regulatory Basis for Pharmacovigilance The framework…

Dashboards and Metrics That Actually Help Run a Case Processing Operation Dashboards and Metrics That Actually Help Run a Case Processing Operation In the evolving landscape of pharmacovigilance, regulatory compliance audits play an essential role in safeguarding public health and ensuring drug safety. This article delves into the structured approach required for effective case processing operations, providing an in-depth review of regulations, metrics, and agency expectations as they relate to ICSR submissions and the interfaces with EudraVigilance and FAERS. Context Regulatory Affairs (RA) professionals in the pharmaceutical and biotech sectors must navigate an intricate web of regulations and guidelines that…